The strategy for enhancing temozolomide against malignant glioma
- PMID: 22912934
- PMCID: PMC3418701
- DOI: 10.3389/fonc.2012.00098
The strategy for enhancing temozolomide against malignant glioma
Abstract
A combined therapy of the alkylating agent temozolomide (TMZ) and radiotherapy is standard treatment, and it improves the survival of patients with newly diagnosed glioblastoma (GBM). The DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) removes the most cytotoxic lesions generated by TMZ, O(6)-methylguanine, establishing MGMT as one of the most important DNA repair mechanisms of TMZ-induced DNA damage. Thus, the expression of MGMT, its activity, and its promoter methylation status are associated with the response of GBM to TMZ, confirming that MGMT promotes clinical resistance to TMZ. Previous studies have shown that a variety of drugs such as interferon-β (IFN-β), levetiracetam (LEV), resveratrol, and valproic acid (VAP) increased the sensitivity of TMZ through MGMT-dependent or MGMT-independent mechanisms. In this review, we describe drugs and promising molecules that influence the responsiveness of GBM to TMZ and discuss their putative mechanism of action. In MGMT-positive GBMs, drugs that modulate MGMT activity could enhance the therapeutic activity of TMZ. Thus, administration of these drugs as an adjunct to TMZ chemotherapy may have clinical applications in patients with malignant gliomas to improve the outcome.
Keywords: MGMT; chemosensitivity; glioma; interferon-β; levetiracetam; resveratrol; temozolomide; valproic acid.
Figures


Similar articles
-
Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.Cancer Chemother Pharmacol. 2020 Dec;86(6):773-782. doi: 10.1007/s00280-020-04169-y. Epub 2020 Oct 19. Cancer Chemother Pharmacol. 2020. PMID: 33074386
-
β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.Cancer Lett. 2018 Oct 28;435:66-79. doi: 10.1016/j.canlet.2018.07.040. Epub 2018 Aug 4. Cancer Lett. 2018. PMID: 30081068
-
20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.Cancer Sci. 2019 Jan;110(1):389-400. doi: 10.1111/cas.13881. Epub 2018 Dec 14. Cancer Sci. 2019. PMID: 30431207 Free PMC article.
-
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.Anticancer Res. 2009 Nov;29(11):4845-54. Anticancer Res. 2009. PMID: 20032445 Review.
-
Temozolomide resistance in glioblastoma multiforme.Genes Dis. 2016 May 11;3(3):198-210. doi: 10.1016/j.gendis.2016.04.007. eCollection 2016 Sep. Genes Dis. 2016. PMID: 30258889 Free PMC article. Review.
Cited by
-
Glycogen Synthase Kinase 3β in Cancer Biology and Treatment.Cells. 2020 Jun 3;9(6):1388. doi: 10.3390/cells9061388. Cells. 2020. PMID: 32503133 Free PMC article. Review.
-
Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT).J Neurooncol. 2024 Aug;169(1):129-135. doi: 10.1007/s11060-024-04708-0. Epub 2024 May 19. J Neurooncol. 2024. PMID: 38762829
-
Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.Cancer Biol Ther. 2017 Dec 2;18(12):917-926. doi: 10.1080/15384047.2017.1385680. Epub 2017 Nov 20. Cancer Biol Ther. 2017. PMID: 29020502 Free PMC article. Review.
-
Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas.Front Oncol. 2013 Mar 4;3:43. doi: 10.3389/fonc.2013.00043. eCollection 2013. Front Oncol. 2013. PMID: 23459853 Free PMC article.
-
Cinnamophilin enhances temozolomide-induced cytotoxicity against malignant glioma: the roles of ROS and cell cycle arrest.Transl Cancer Res. 2021 Sep;10(9):3906-3920. doi: 10.21037/tcr-20-3426. Transl Cancer Res. 2021. PMID: 35116690 Free PMC article.
References
-
- Agnihotri S., Gajadhar A. S., Ternamian C., Gorlia T., Diefes K. L., Mischel P. S., Kelly J., McGown G., Thorncroft M., Carlson B. L., Sarkaria J. N., Margison G. P., Aldape K., Hawkins C., Hegi M., Guha A. (2012). Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J. Clin. Invest. 122, 253–266 10.1172/JCI59334 - DOI - PMC - PubMed
-
- Agnihotri S., Wolf A., Munoz D. M., Smith C. J., Gajadhar A., Restrepo A., Clarke I. D., Fuller G. N., Kesari S., Dirks P. B., McGlade C. J., Stanford W. L., Aldape K., Mischel P. S., Hawkins C., Guha A. (2011). A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J. Exp. Med. 208, 689–702 10.1084/jem.20102099 - DOI - PMC - PubMed
-
- Barker C. A., Burgan W. E., Carter D. J., Cerna D., Gius D., Hollingshead M. G., Camphausen K., Tofilon P. J. (2006). in vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhi-bitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). Clin. Cancer Res. 12, 2912–2918 10.1158/1078-0432.CCR-05-2860 - DOI - PubMed
-
- Bobola M. S., Tseng S. H., Blank A., Berger M. S., Silber J. R. (1996). Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin. Cancer Res. 2, 735–741 - PubMed
LinkOut - more resources
Full Text Sources
Research Materials